Search Open Mobile Menu

Veracyte® Investor Relations

Veracyte is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of diagnostic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment.
The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its genomic tests to patients worldwide. Veracyte is based in South San Francisco, California.

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 15, 2023-- Veracyte, Inc. (Nasdaq: VCYT) announced today that three abstracts highlighting the company’s unique, multi-omics capabilities and offerings for biopharmaceutical partners will be presented at the American Association for Cancer
Toggle Summary Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 11, 2023-- Veracyte, Inc. (Nasdaq: VCYT) outlined the company’s cash, cash equivalents and short-term investment status in light of the events surrounding Silicon Valley Bank (SVB). As of December 31, 2022 , the company had $178.9 million in cash,


Date Event Details
Summary Toggle Mar 21, 2023 3:45 PM EDT
KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum


Title Documents

Corporate Presentation March 2023